Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer

Inclusion criteria

• age ≥ 18 < 80 years old
• recent diagnosis (< 48h) of rectum or colon cancer, established by endoscopy and later confirmed by anatomo-pathologic study
• normal coagulation values and biochemical vales without clinically significant deviations that, at the discretion of the investigator, may interfere with the study procedures

Exclusion criteria

• Allergy to ASA or to any other NSAID.
• Rectal cancer requiring neoadjuvant treatment within the two weeks following the beginning of ASA treatment.
• Previous use of ASA, NSAIDs, antiplatelet agents, corticosteroids or misoprostol within the 15 days prior to diagnosis and/or anticipation of need for treatment with any of these drugs during the study period. History of peptic ulcer disease or active peptic ulcer or any other gastrointestinal disease that may be considered a contraindication to the use of ASA, without the concomitant use of proton pump inhibitors.
• Diagnosis of bleeding disorders.
• Diagnosis of cancer (excluding non-melanoma skin cancer) within the previous 3 years.
• Conditions supposing serious comorbidity, excluding diabetes, and including respiratory, cardiac, hepatic and renal diseases.
• Active smoking.
• Pregnancy or breastfeeding.
• History of drug or alcohol abuse.